Evaluating Use Patterns of and Adherence to Medications for Benign Prostatic Hyperplasia

Journal of Urology

Volumn 181, Issue 5, 2009, Pages 2214-2222

  Nichol, Michael B ^a   Knight, Tara K ^a   Wu, Joanne ^a   Barron, Richard ^c   Penson, David F ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c ALLERGAN INC   (United States)

Author keywords

adrenergic alpha antagonists; Medicaid; medication adherence; prostate; prostatic hyperplasia

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; FINASTERIDE; TAMSULOSIN; TERAZOSIN;

ADULT; ARTICLE; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATIENT COMPLIANCE; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE HYPERTROPHY;

ADULT; AGE FACTORS; AGED; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FINASTERIDE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PATIENT DROPOUTS; PROBABILITY; PROPORTIONAL HAZARDS MODELS; PROSTATIC HYPERPLASIA; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 64049100746     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.01.033     Document Type: Article

References (25)

1. Stoevelaar H.J., and McDonell J. Changing therapeutic regimens in benign prostatic hyperplasia. Pharmacoeconomics 19 (2001) 131
2. Anderson J.B., Roehrborn C.G., Schalken J.A., and Emberton M. The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur Urol 39 (2001) 390
3. Marberger M., Harkaway R., and de la Rosette J. Optimising the medical management of benign prostatic hyperplasia. Eur Urol 45 (2004) 411
4. Schulman C.C. Impact of treatment on sexuality. Prostate Cancer Prostatic Dis 4 suppl. (2001) S12
5. Debruyne F.M.J. Medical management of BPH: the debate continues. Eur Urol 50 (2006) 416
6. Lowe F.C. Role of the newer alpha, adrenergic receptor antagonists in the treatment of benign prostatic hyperplasia related lower urinary tract symptoms. Clin Ther 26 (2004) 1701
7. McConnell J.D., Bruskewitz R., Walsh P., Andriole G., Lieber M., Holtgrewe L., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long Term Efficacy and Safety Group. N Engl J Med 338 (1998) 557
8. Verhamme K.M.C., Dieleman J.P., Bleumink G.S., Bosch J.L.H.R., Stricker B.H.C., and Sturkenboom M.C.J.M. Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph Project. Eur Urol 44 (2003) 539
9. Deyo R.A., Cherkin D.C., and Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45 (1992) 613
10. Peterson A.M., Nau D.P., Cramer J.A., Benner J.S., Gwadry-Sridhar F., and Nichol M.B. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 10 (2006) 3
11. Benner J.S., Glynn R.J., Mogun H., Neumann P.J., Weinstein M.C., and Avorn J. Long-term persistence in the use of statin therapy in elderly patients. JAMA 288 (2002) 455
12. Avorn J., Monette J., Lacour A., Bohn R.L., Monane M., Mogun H., et al. Persistence of use in lipid-lowering medications: a cross national study. JAMA 279 (1998) 1458
13. Puppo P., Desgrandchamps F., Castro-Diaz D., and Madersbacher S. Alternatives to TURP: outcome analysis and indication tuning. Eur Urol 42 (2002) I
14. Boyle P., Roehrborn C., Harkaway R., Logie J., de laRosette J., and Emberton M. 5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery. Eur Urol 45 (2004) 620
15. Kirby R.S. Terazosin in benign prostatic hyperplasia: effects on blood pressure in normotensive and hypotensive men. BJU 82 (1998) 373
16. Kaplan S.A., and D'Allisera P.M. Tolerability of a alpha-blockade with doxazosin as a therapeutic option for symptomatic benign prostatic hyperplasia in the elderly patient: a pooled analysis of seven double-blind, placebo-controlled studies. J Gerontol A Biol Sci Med Sci 53 (1998) M201
17. McConnell J., Roehrborn C.G., Bautista O.M., Andriole G.L., Dixon C.M., Kusek J.W., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387
18. Chapman R.H., Benner J.S., Petrilla A.A., Tierce J.C., Collins S.R., Battleman D.S., et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Int Med 165 (2005) 1147
19. Jackevicius C.A., Mamdani M., and Tu J.V. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 288 (2002) 462
20. Grant R.W., Devita N.G., Singer D.E., and Meigs J.B. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care 26 (2003) 1408
21. Souverein P., Erkens J.A., de la Rosette J., Leufkens H.G.M., and Herings R.M.C. Drug treatment of benign prostatic hyperplasia and hospital admission for BPH-related procedure. Eur Urol 43 (2003) 528
22. Kim C.I., Chang H.S., Kim B.K., and Park C.H. Long term results of medical treatment in benign prostatic hyperplasia. Urology 68 (2006) 1015
23. Black L., Naslund M.J., Gilbert T.D., Davis A., and Ollendorf D.A. An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia. Am J Manag Care 12 (2006) S99
24. Christenson D.B., Williams B., Goldberg H.L., Martin D.P., Engleberg R., and LoGerfo J.P. Comparison of prescription and medical records in reflecting patient antihypertensive drug therapy. Pharmacotherapy 28 (1994) 99
25. Choo P.W., Rand C.S., Inui T.S., Lee M.L., Cain E., Cordeiro-Breault M., et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 37 (1999) 846